Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Dexcom G6 is now covered by RAMQ, BC PharmaCare, and Saskatchewan Health


The Dexcom G6 CGM System is now covered in Québec by RAMQ, in British Columbia by BC PharmaCare, and in Saskatchewan by Saskatchewan Health. Conditions apply. Click the links below for more information.


Quebec (RAMQ)

British Columbia (BC PharmaCare)

Saskatchewan (Saskatchewan Health)

Who can benefit?

Identifying CGM candidates

Despite their best intentions and efforts, many patients with diabetes struggle to maintain optimal glycemic control. Dexcom CGM can benefit the following:
  • Patients with Type 1 or Type 2 diabetes on mealtime insulin,
  • Patients on multiple daily injections (MDI) or an insulin pump,
  • Patients at risk for hypoglycemia,
  • Patients who may experience hypoglycemia unawareness,
  • Patients who want a better way to meet their glycemic goals,
  • Patients experiencing excessive glycemic variability, or
  • Patients who may benefit from sharing their glucose data with a loved one
    (e.g., children, older adults, etc.)
Better diabetes treatment decisions

More insight than monitoring alone

Unlike a single reading from a blood glucose meter, continuous glucose monitoring (CGM) systems provide patients with continuous information every 5 minutes. CGM gives patients their current glucose level, speed and direction of glucose change, giving them timely feedback necessary for nutrition, activity, and insulin requirements.

CGM is a powerful management tool that can inform better diabetes treatment decisions, and ultimately leads to tighter glycemic control than using a blood glucose meter alone.1
Significant A1C reductions

CGM Usage in MDI Patients

There are commonly held beliefs in the diabetes community that patients on multiple daily injections (MDI) won’t benefit from CGM because they either wouldn't be willing to wear a CGM device or they would find it too complicated to use.

The DIaMonD study provides compelling evidence that challenged these misperceptions and showed that when using CGM, MDI patients experience significant A1C reductions regardless of education level, diabetes numeracy or age.2
Patients demonstrated significant A1C reductions (avg of 1%), regardless of education level, diabetes numeracy, and age
Keep up with the latest news and information.

Stay up-to-date
with Dexcom

Sign up to stay up-to-date with the latest CGM news, product updates and educational events.
1 Pettus J, Price DA, Edelman SV. Endocr Pract. 2015;1-25.
2 Beck RW, et al. JAMA 2017;317:371-78.